Last reviewed · How we verify
NCT05645471
Together After Cancer
NA trial testing Together After Cancer in Breast Cancer in 480 participants. Currently enrolling.
31 July 2025
Quick facts
| Lead sponsor | University of South Florida |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 480 |
| Start date | 1 January 2023 |
| Primary completion | 31 July 2025 |
| Estimated completion | 1 March 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Together After Cancer
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Quality of Life — all drugs for Quality of Life →
- Communication — all drugs for Communication →
Sponsor
University of South Florida
Who can join
Adults 18 to 80, any sex, with Breast Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the impact of an adapted online, self-help relationship intervention (supplemented with brief coach calls) for survivors of breast cancer and their partners. Couples will be randomized to receive either the online intervention (Together after Cancer) or usual care (UC) and assessed at baseline, end of the program, and 3 months after randomization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05645471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of South Florida trials
Trials by the same sponsor.
- NCT07529366 — Pharmacist-Led Continuous Glucose Monitoring for Prediabetes · recruiting
- NCT07342569 — The WeACT Program for Family Caregivers of People Living With Dementia · NA · not yet recruiting
- NCT07502378 — Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic · Phase 4 · recruiting
- NCT07241260 — Hydrate Heroes for Improving Brain Function & Mood · NA · not yet recruiting
- NCT06377215 — Understanding Aided Speech Perception in Noise · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05645471 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of South Florida
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05645471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing